mark trudeau, the president and ceo of mallinckrodt pharmaceuticals. welcome.at. >> this is a little unexpected and a bit controversial as we know from the conference call, but first, this givious access to a very important drug that people think could be good for lupus, als, rheumatoid arthritis, and at the same time it also gives you tax benefits. would you have done this deal even just because of the tax benefits? >> absolutely, jim, this is a product that we believe has significant growth opportunities and moreover, it's complimentary to what we do as a business. our focus has been to build growth platforms and focus specialty tarm farms. we believe the questcor acquisition and actar enables us to fully develop our growth opportunities areas that where we do have expertise. >> you did go over how they're created with the irish domicile. >> it makes complete sense for us because the product and the company have been growing very, very well. the product is very profitable and the company is very profitable and it adds size and scale to our business as well as